Integra LifeSciences To Spotlight CereLink Intracranial Pressure Monitoring System At The American Association Of Neurological Surgeons Annual Scientific Meeting
Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, is pleased to announce that following a successful Q1 2024 U.S. relaunch of its CereLink ICP Monit
Buy Rating for Integra Lifesciences Amid Favorable Medicare Policy Changes
Jefferies Sticks to Their Buy Rating for Integra Lifesciences (IART)
Integra LifeSciences Shares Are Trading Lower. The Company Announced It Will Reschedule Its Q1 Financial Results Conference Call.
Integra LifeSciences Shares Are Trading Lower. The Company Announced It Will Reschedule Its Q1 Financial Results Conference Call.
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it has rescheduled the release of the
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
Here's Why Investors Should Retain Integra (IART) Stock Now
Top Buy-rated Stocks and Sell-rated Stocks Within Health Care - Citi
Integra LifeSciences Raised to Neutral From Sell by Citigroup
Integra LifeSciences Raised to Neutral From Sell by Citigroup
Citigroup Upgrades Integra LifeSciences to Neutral From Sell, Price Target Is $38
Integra LifeSciences Holdings (IART) has an average rating of hold and price targets ranging from $37 to $57, according to analysts polled by Capital IQ.
Integra LifeSciences Completes Acquisition of J&J's Acclarent
Integra LifeSciences Completes The Acquisition Of Acclarent, Inc. >IART
Integra LifeSciences Completes The Acquisition Of Acclarent, Inc. >IART
Press Release: Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced it has successfully completed its acquisition of Acclarent, Inc., a pioneer in ear, nose and throat (ENT) surgical interventions.
Integra LifeSciences Holdings' (NASDAQ:IART) Earnings Have Declined Over Three Years, Contributing to Shareholders 48% Loss
Why Is Integra (IART) Down 4% Since Last Earnings Report?
Are Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
It is hard to get excited after looking at Integra LifeSciences Holdings' (NASDAQ:IART) recent performance, when its stock has declined 21% over the past month. However, stock prices are usually dri
11 Oversold Healthcare Stocks To Buy Right Now
Some May Be Optimistic About Integra LifeSciences Holdings' (NASDAQ:IART) Earnings
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) earnings announcement last week didn't impress shareholders. While the headline numbers were soft, we believe that investors might be missing
Integra LifeSciences (IART) Introduces MicroMatrix Flex
Integra LifeSciences Launches MicroMatrix Flex to Provide Convenient Access to Hard-to-Reach Areas in Complex Cases
PRINCETON, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), today announced MicroMatrix Flex is now available commercially in the U.S. MicroMatrix Flex is a
No Data